Businesses Owned By Gus Attridge
Businesses Owned By Gus Attridge. Michael Guy Attridge, known as Gus Attridge is a South African businessman. He is the deputy CEO of Aspen Pharmacare, which he co-founded with Stephen Saad in 1997. In 2013 Attridge’s 4% personal stake in the company was valued at over $320 million. He is also a member of the Social & Ethics Committee and attends meetings of all of the other Board Committees by invitation. According to Entrepreneur Mag Attridge has an estimated net worth of R5. 7 Billion. Below are some of the businesses owned by Gus Attridge.
Aspen Pharmacare
Aspen Pharmacare bills itself as the world’s fifth largest generic drugmaker. It expanded its global footprint with a slew of acquisitions in 2013. Aspen manufactures drugs in factories around the world, including in Australia, Brazil, Mexico, Germany, South Africa and Tanzania. After complaints of anticompetitive activities by Boehringer Ingelheim and GlaxoSmithKline in 2003, Aspen was granted licenses from the companies to create generic versions of antiretrovirals (ARV) for use in the Sub-Saharan portion of Africa.
Shelys Pharmaceuticals
Shelys Pharmaceuticals is a renowned pharmaceutical company of Sub Saharan Africa. Shelys has humble origins starting as a diminutive family business in 1956 and has, over the years, established itself to be one of the largest pharmaceutical companies in East Africa. Shelys has its footprints in Tanzania ,Zambia ,Malawi ,DRC, Rwanda , Burundi, Mozambique, Madagascar ,Mauritius, Djibouti ,Uganda and Kenya and is a leader in the script market for crucial therapeutic categories such as cough and cold, anti infectives, nutraceuticals, antimalarials, gastro intestinal, pain management, fever and topical inflammation, disinfectants and cardiovascular range.
Fine Chemicals Corporation
The business of Fine Chemicals Corporation was established in Cape Town, South Africa in 1962. Initially, products including Codeine Phosphate, Morphine Sulphate and Paracetamol were targeted at the local South African market and in the mid 1980’s a range of off patent generic API’s were developed in-house. These were largely destined for the US market.
